日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation

新型TEAD1抑制剂VT103通过下调Survivin增强达拉非尼在BRAF V600E突变肺腺癌中的疗效

期刊:Cancer Science
影响因子:4.3
doi:10.1111/cas.70075
Hosoya, Kazutaka; Ozasa, Hiroaki; Yoshida, Hironori; Ajimizu, Hitomi; Tsuji, Takahiro; Yamazoe, Masatoshi; Ogimoto, Tatsuya; Hashimoto, Kentaro; Funazo Yamamoto, Tomoko; Suminaga, Keiichiro; Shima, Yusuke; Yoshida, Hiroshi; Nomizo, Takashi; Ito, Hiroaki; Terada, Kazuhiro; Nishikawa, Shigeto; Menju, Toshi; Yoshizawa, Akihiko; Date, Hiroshi; Hirai, Toyohiro
Survivin
肿瘤
BRAF
肿瘤免疫
发表日期：2025
文献求助 收藏

Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study

培美曲塞治疗肾功能不全的非小细胞肺癌患者的安全性和有效性：一项回顾性研究

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-025-13785-x
Shima, Yusuke; Yoshida, Hironori; Suminaga, Keiichiro; Yoshida, Hiroshi; Hashimoto, Kentaro; Ogimoto, Tatsuya; Hosoya, Kazutaka; Ajimizu, Hitomi; Funazo, Tomoko; Nomizo, Takashi; Ozasa, Hiroaki; Hirai, Toyohiro
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Durvalumab consolidation after chemoradiotherapy for locoregional recurrent non-small cell lung cancer

度伐利尤单抗巩固治疗局部区域复发性非小细胞肺癌放化疗后

期刊:Molecular and Clinical Oncology
影响因子:1.4
doi:10.3892/mco.2025.2879
Suminaga, Keiichiro; Yoshida, Hironori; Shima, Yusuke; Yoshida, Hiroshi; Hashimoto, Kentaro; Ogimoto, Tatsuya; Hosoya, Kazutaka; Funazo, Tomoko; Ajimizu, Hitomi; Nomizo, Takashi; Yoneyama, Masahiro; Kishi, Noriko; Ozasa, Hiroaki; Hirai, Toyohiro
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer.

Yes 相关蛋白 1 通过 AKT 信号传导介导 ROS1 重排肺癌中洛拉替尼治疗期间的初始细胞存活

期刊:Cancer Science
影响因子:4.3
doi:10.1111/cas.15622
Yamazoe Masatoshi, Ozasa Hiroaki, Tsuji Takahiro, Funazo Tomoko, Yoshida Hiroshi, Hashimoto Kentaro, Hosoya Kazutaka, Ogimoto Tatsuya, Ajimizu Hitomi, Yoshida Hironori, Itotani Ryo, Sakamori Yuichi, Kuninaga Kiyomitsu, Aoki Wataru, Hirai Toyohiro
信号转导
细胞生物学
PI3K/Akt
肿瘤免疫
发表日期：2023
文献求助 收藏

CD47 polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer

CD47多态性预测晚期非小细胞肺癌患者接受纳武利尤单抗治疗的获益

期刊:Oncology Letters
影响因子:2.2
doi:10.3892/ol.2023.13950
Ogimoto, Tatsuya; Ozasa, Hiroaki; Yoshida, Hironori; Nomizo, Takashi; Funazo, Tomoko; Yoshida, Hiroshi; Hashimoto, Kentaro; Hosoya, Kazutaka; Yamazoe, Masatoshi; Ajimizu, Hitomi; Tsuji, Takahiro; Sakamori, Yuichi; Kuninaga, Kiyomitsu; Morita, Satoshi; Hirai, Toyohiro
肺癌
肿瘤
T细胞
肿瘤免疫
CD47
细胞生物学
CD4
发表日期：2023
文献求助 收藏

Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series

使用纳武利尤单抗治疗肉瘤样恶性胸膜间皮瘤：病例系列

期刊:Oncology Letters
影响因子:2.2
doi:10.3892/ol.2022.13522
Hashimoto, Kentaro; Ozasa, Hiroaki; Yoshizawa, Akihiko; Yoshida, Hiroshi; Ogimoto, Tatsuya; Hosoya, Kazutaka; Yamazoe, Masatoshi; Ajimizu, Hitomi; Funazo, Tomoko; Yoshida, Hironori; Sakamori, Yuichi; Hirai, Toyohiro
发表日期：2022
文献求助 收藏

Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer

慢性阻塞性肺疾病治疗对晚期非小细胞肺癌患者生存率的影响

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-021-03139-5
Ajimizu, Hitomi; Ozasa, Hiroaki; Sato, Susumu; Funazo, Tomoko; Sakamori, Yuichi; Nomizo, Takashi; Kuninaga, Kiyomitsu; Ogimoto, Tatsuya; Hosoya, Kazutaka; Yamazoe, Masatoshi; Tsuji, Takahiro; Yoshida, Hironori; Itotani, Ryo; Ueno, Kentaro; Kim, Young Hak; Muro, Shigeo; Hirai, Toyohiro
肺癌
肿瘤
肿瘤免疫
慢性阻塞性肺疾病
细胞生物学
发表日期：2021
文献求助 收藏

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation

YAP1通过调控促凋亡蛋白介导ALK重排肺癌细胞在阿来替尼治疗后的存活。

期刊:Nature Communications
影响因子:14.7
doi:10.1038/s41467-019-13771-5
Takahiro Tsuji,Hiroaki Ozasa,Wataru Aoki,Shunsuke Aburaya,Tomoko Yamamoto Funazo,Koh Furugaki,Yasushi Yoshimura,Masatoshi Yamazoe,Hitomi Ajimizu,Yuto Yasuda,Takashi Nomizo,Hironori Yoshida,Yuichi Sakamori,Hiroaki Wake,Mitsuyoshi Ueda,Young Hak Kim,Toyohiro Hirai
肺癌
细胞生物学
肿瘤
信号转导
表观遗传
ALK
YAP1
YAP
凋亡
发表日期：2020
文献求助 收藏

MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression

MCL1 抑制对具有高 MCL1 和低 BCL-XL 表达的一组小细胞肺癌有效

期刊:Cell Death & Disease
影响因子:8.1
doi:10.1038/s41419-020-2379-2
Yuto Yasuda, Hiroaki Ozasa, Young Hak Kim, Masatoshi Yamazoe, Hitomi Ajimizu, Tomoko Yamamoto Funazo, Takashi Nomizo, Takahiro Tsuji, Hironori Yoshida, Yuichi Sakamori, Naoki Nakajima, Toshi Menju, Akihiko Yoshizawa, Hiroshi Date, Toyohiro Hirai
肿瘤
肺癌
其它细胞
发表日期：2020
文献求助 收藏

Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab

低血清游离T4水平对接受纳武利尤单抗治疗的非小细胞肺癌患者的临床影响

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-019-53327-7
Funazo, Tomoko Yamamoto; Nomizo, Takashi; Ozasa, Hiroaki; Tsuji, Takahiro; Yasuda, Yuto; Yoshida, Hironori; Sakamori, Yuichi; Nagai, Hiroki; Hirai, Toyohiro; Kim, Young Hak
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2019
文献求助 收藏